Thiazolidinediones in the treatment of type 2 diabetes

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 5, 2002, Pages 529-540

  Pittas, Anastassios G ^a   Greenberg, Andrew S ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidiabetic drugs; Insulin resistance syndrome; Metabolic syndrome; Pioglitazone; PPAR ; Rosiglitazone; Thiazolidinedione; Troglitazone; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ADIPONECTIN; ALANINE AMINOTRANSFERASE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; CELL NUCLEUS RECEPTOR; DEXTRO PHENYLALANINE; FATTY ACID; GLIBENCLAMIDE; GLUCOSE; GLUCOSE TRANSPORTER 4; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; KETOCONAZOLE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEGLITINIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; ORAL CONTRACEPTIVE AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA; TOLBUTAMIDE; TROGLITAZONE; UNINDEXED DRUG;

CARDIOTOXICITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETIC OBESITY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG COST; DRUG INHIBITION; DRUG METABOLISM; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; DYSLIPIDEMIA; GASTROINTESTINAL SYMPTOM; GLUCOSE METABOLISM; HUMAN; HYPERCOAGULABILITY; HYPERTENSION; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LIPODYSTROPHY; LIVER FAILURE; LIVER TOXICITY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; REVIEW;

COSTS AND COST ANALYSIS; DIABETES MELLITUS, TYPE 1; HUMANS; HYPOGLYCEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0036093876     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.5.529     Document Type: Review

References (69)

1. The continuing epidemics of obesity and diabetes in the United States
2. Pathophysiology and pharmacological treatment of insulin resistance
3. Role of insulin resistance in human disease (syndrome X): An expanded definition
4. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33)
5. Oral antihyperglycemic therapy for Type 2 diabetes: Scientific review
6. Troglitazone
7. New oral thiazolidinedione antidiabetic agents act as insulin sensitizers
8. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR-γ)
9. PPAR-γ: A nuclear regulator of metabolism, differentiation and cell growth
10. Adipose tissue is required for the antidiabetic but not for the hypolipidemic, effect of thiazolidinediones
11. Troglitazone action is independent of adipose tissue
12. Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity
13. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation
14. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with Type 2 diabetes
15. Tumour necrosis factor α: A key component of the obesity-diabetes link
16. TNF-α-induced insulin resistance in vivo and its prevention by troglitazone
17. Thiazolidinediones block tumour necrosis factor-α-induced inhibition of insulin signalling
18. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats
19. Normalization of plasma lipid peroxides, monocyte adhesion and tumour necrosis factor-α production in NIDDM patients after gliclazide treatment
20. Elevated serum levels of macrophage-derived cytokines precede and accompany the onset of IDDM
21. Altered immune function in a morbidly obese pediatric population
22. Peroxisome proliferator-activated receptors in macrophage biology: Friend or foe?
23. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM
24. Improved glycemic control and enhanced insulin sensitivity in Type 2 diabetic subjects treated with pioglitazone
25. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues
26. Increased adipose tissue expression of tumour necrosis factor-α in human obesity and insulin resistance
27. Stimulation of lipolysis in cultured fat cells by tumour necrosis factor, interleukin-1 and the interferons is blocked by inhibition of prostaglandin synthesis
28. BRL 49653 blocks the lipolytic actions of tumour necrosis factor-α: A potential new insulin-sensitizing mechanism for thiazolidinediones
29. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action
30. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice
31. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity
32. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity
33. PPAR-γ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein
34. The hormone resistin links obesity to diabetes
35. Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance
36. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death
37. Potentiation of glucose uptake in 3T3-L1 adipocytes by PPAR γ agonists is maintained in cells expressing a PPAR γ dominant- negative mutant: Evidence for selectivity in the downstream responses to PPAR γ activation
38. Troglitazone monotherapy improves glycemic control in patients with Type 2 diabetes mellitus: A randomized, controlled study
39. Troglitazone in combination with sulfonylurea restores glycemic control in patients with Type 2 diabetes
40. Effect of troglitazone in insulin-treated patients with Type II diabetes mellitus
41. Long-term effects of troglitazone: Open-label extension studies in Type 2 diabetic patients
42. Rosiglitazone monotherapy is effective in patients with Type 2 diabetes
43. Effect of metformin and rosiglitazone combination therapy in patients with Type 2 diabetes mellitus: A randomized controlled trial
44. Rosiglitazone improves glycemic control in poorly controlled, insulin-treated Type 2 diabetes
45. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with Type 2 diabetes: A 6-month randomized placebo-controlled dose-response study
46. Durability of glycemic control with pioglitazone in long-term combination and monotherapy
47. Risk factor clustering in the insulin resistance syndrome. The Strong Heart Study
48. Thiazolidinediones, dyslipidaemia and insulin resistance syndrome
49. Comparison of effects of thiazolidinediones on cardiovascular risk factors: Observations from a clinical practice
50. A prospective, randomized comparison of the metabolic effects of pioglitazone versus rosiglitazone in patients with Type 2 diabetes who were previously treated with troglitazone
51. A PPAR-γ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis
52. Cardiac and glycemic benefits of troglitazone treatment in NIDDM
53. Group FTGPS: Pioglitazone reduces blood pressure in patients with Type 2 diabetes mellitus
54. Atherosclerosis - An inflammatory disease
55. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction
56. Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with Type II diabetes
57. The effect of treatment with rosiglitazone on C-reactive protein and interleukin-6 in patients with Type 2 diabetes
58. Plasma fibrinogen: A new factor of the metabolic syndrome. A population-based study
59. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients-relationship with plasma insulin
60. Effect of troglitazone on fibrinolysis and activated coagulation in patients with noninsulin-dependent diabetes mellitus
61. Plasminogen activator inhibitor type-1 (PAI-1) and its role in cardiovascular disease
62. Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy
63. Hepatocellular injury in a patient receiving rosiglitazone. A case report
64. Hepatic failure in a patient taking rosiglitazone
65. Prevention of Type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance
66. Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin
67. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome
68. Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus